Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-01
2007-05-01
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S328000
Reexamination Certificate
active
10405088
ABSTRACT:
The present invention provides for a novel peptidic antagonist for the bradykinin B1 (BKB1) receptor having very good to excellent affinities and selectivity for the BKB1receptor, in vitro and in vivo increase resistance to enzymatic degradation, superior pharmacokinetic properties, capability to significantly reduce microvascular leakage observed alongside diabetic-induced increase in vascular permeability, capability to significantly reduced the state of hyperalgesia alongside diabetes, capability to significantly reduce the infiltration of pro-inflammatory cells and general state of inflammation alongside allergic asthma.
REFERENCES:
patent: 5610140 (1997-03-01), Goodfellow et al.
patent: 5635593 (1997-06-01), Cheronis et al.
patent: 5700779 (1997-12-01), Goodfellow et al.
patent: 5750506 (1998-05-01), Goodfellow et al.
patent: 5834431 (1998-11-01), Stewart et al.
patent: 5843900 (1998-12-01), Cheronis et al.
patent: 5849312 (1998-12-01), Breton et al.
patent: 5849863 (1998-12-01), Stewart et al.
patent: 5863899 (1999-01-01), Cheronis et al.
patent: 6015812 (2000-01-01), Ferrari et al.
patent: 6075120 (2000-06-01), Cheronis et al.
patent: 6241993 (2001-06-01), Breton et al.
patent: 6468972 (2002-10-01), Pruche et al.
patent: 2004/0198666 (2004-10-01), Regoli et al.
patent: WO97/09346 (1997-03-01), None
patent: WO97/25315 (1997-07-01), None
patent: WO98/07746 (1998-02-01), None
patent: WO00/75107 (2000-12-01), None
patent: WO01/05783 (2001-01-01), None
Bedos, et al.,J. Med. Chem., 43: 2387-2394, (2000).
Béliveau,et al.,Clinical Cancer Research, 8:1242-1250, (2002).
Bhargava and Zhao,Neuropeptides, 30:219-223, (1996).
Bhoola et al.,Pharmacol. Rev., 44:1-80, (1992).
Chakir and Plante,Prostagl. Leukot. Essent. Fatty Acids, 54:45-51, (1996).
Coderre and Rollman,Life Sci., 32:2139-2146, (1983).
D'Amour and Smith,J. Pharmacol. Exp. Ther., 72:74-79, (1941).
Davis et al.,Brazilian J. Med. Bil Res.., 27:1793-1802, (1994).
Drapeau et al.,J. Pharmacol. Exp. Ther., 259:997-1003, (1991).
Drapeau et al.,J. Pharmacol. Exp. Ther., 266:192-198, (1993).
Drapeau and Regoli,Methods in Enzymol, 163:263-272, (1988).
Dray and Perkins,Trends Neurosci., 16:99-104, (1993).
Eddy and Leimbach,J. Pharmacol. Exp. Ther., 107:385-389, (1953).
Erdös and Skidgel,Hypertension, 8:34-37, (1986).
Erdös and Skidgel, “The Kinin System”,Academic Press, London, U.K., pp. 111-141, (1997).
Farmer, “The Kinin System”,Academic Press, London, U.K., pp. 249-263, (1997).
Ferreira and Vane,Br. J. Pharmacol., 108:124-143, (1967).
Gabra and Sirois,11thNational Conference of the Inflammation Research Association, Bolton Landing, NY U.S.A. (Poster and Oral Presentation; Inflamm. Res. Abst., (2002).
Gabra and Sirois,62ndScientific Sessions of the Am. Diabetes Ass., San Francisco, CA, U.S.A. (Poster Presentation-Late Breaking Abstract), (2002).
Gabra and Sirois,Eur. J. Pharmacol., 457(2-3):115-24, (2002).
Gama Landgraf et al.,Eur. J. Pharmacol., 460(1):75-83, (2003).
Gaudreau et al.,Can. J. Physiol Pharmacol., 59:371-379, (1981).
Gobeil et al.,Br. J. Pharmacol., 118:289-294, (1996).
Gobeil et al.,Can. J. Physiol. Pharmacol., 74:137-144, (1996).
Gobeil et al.,Hypertension, 28:833-839, (1996).
Gobeil et al.,Hypertension, 33:823-829, (1999).
Hargreaves et al.,Pain, 32:77-88, (1988).
Hilgenfeldt et al.,Analyt. Biochem., 228:35-41, (1995).
Horlick et al.,Immunopharmacol., 43:169-177, (1999).
Kung et al.,Int. Arch. Allergy Immunol., 105:83-90, (1994).
Larrivée et al.,Br. J. Pharmacol., 131:885-892, (2000).
Maggiora et al.,J. Med. Chem., 42:2394-2402, (1999).
Marceau et al.,Pharmacol. Rev., 50:357-386, (1998).
Marceau,Immunopharmacol., 30:1-26, (1995).
Mason et al.,Can. J. Physiol. Pharmacol., 80:264-268, (2002).
McEvoy et al.,J. Clin. Invest., 74:715-722, (1984).
Menke et al.,J. Biol. Chem., 269:21583-21586, (1994).
Miskolzie et al.,J Biomol. Struc.t Dyn., 19:585-593, (2002).
Neugebauer et al.,Can. J. Physiol. Pharmacol., 80:287-292, (2002).
Neugebauer et al.,Proceedings of The 27thEuropean Peptide Society Symposium, Sorrento, Italy, (Aug. 31-Sep. 6, 2002).
Ozturk et al.,Curr. Pharma. Des., 7:135-161, (2001).
Perron et al.,Eur. J. Pharmacol., 376:83-89, (1999).
Plante et al.,Can. J. Physiol Pharmacol., 74:824-833, (1996).
Regoli et al.,Can. J. Physiol. Pharmacol., 55:855-867, (1977).
Regoli et al.,Eur. J. Pharm., 348:1-10, (1998).
Regoli et al.,Embryonic Encyclopedia of Life Sciences, No. 785998, pp. 1-9, (1999).
Regoli and Barabé,Pharmacol. Rev., 32:1-46, (1980).
Regoli, Park, and Rioux,Can. J. Physiol. Pharmacol., 51:114-121, (1973).
Schild,Brit. J. Pharmacol., 2:189-206, (1947).
Sirois et al.,16thInt. Symposium on Kallikrein-Kinin System, Charleston, SC, USA (Abst), (2002).
Skidgel and Erdös,Immunol. Rev., 161:129-141, (1998).
Stewart et al.,Can. J. Physiol. Pharmacol., 75:719-724, (1997).
Stewart et al.,Can. J. Physiol. Pharmacol., 80:275-280, (2002).
Zuccollo et al.Can. J. Physiol. Pharmacol., 74:586-589, (1996).
Gabra Bichov
Gobeil Fernand
Neugebauer Witold
Regoli Domenico
Sirois Pierre
Cordero Garcia Marcela M
Nixon & Peabody LLP
Tsang Cecilia J
Universite De Sherbrooke
LandOfFree
Selective bradykinin (BK) B1 peptidic receptor antagonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective bradykinin (BK) B1 peptidic receptor antagonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective bradykinin (BK) B1 peptidic receptor antagonists... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3786414